A Meta-analysis of Severe Acute Respiratory Syndrome Coronavirus 2 Anti-spike Immunoglobulin G Antibody Durability up to 9 Months After Full Vaccination in Adults.

Publication date: Mar 01, 2025

This meta-analysis aims to estimate temporal decline in vaccine-induced antibodies against severe acute respiratory syndrome coronavirus 2 up to 9 months after full vaccination contributing to overall understanding of coronavirus disease 2019 infection protection. We identified 15 eligible studies and calculated standardized mean differences (SMD) between antibody concentrations at 1, 3, 6, and 9 months after full vaccination. Overall SMD between 1 month after vaccination and 3 months was -1. 14 (95% CI -1. 52, -0. 76), at 6 months was -1. 06 (95% CI -1. 30, -0. 81), and at 9 months, it was -0. 77 (95% CI -0. 94, -0. 60) suggesting a moderate decline over time.

Concepts Keywords
3months Adult
Coronavirus Antibodies
Lab Antibodies, Viral
Vaccination Antibodies, Viral
Antibody durability
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
Humans
Immunoglobulin G
Immunoglobulin G
mRNA vaccine
SARS-CoV-2
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2
Vaccination

Semantics

Type Source Name
disease MESH coronavirus disease 2019
disease MESH infection

Original Article

(Visited 2 times, 1 visits today)